Möchten Sie immer auf dem neuesten Stand bleiben?

Acquires Orphan Drug Designation for betahistine for the treatment of obesity associated with Prader-Willi syndrome (PWS) Signs letter of intent to in-license two US patents covering use of...

Zug, Switzerland, November 20, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...

Positive outcomes from second Phase 1 trial with intranasal betahistine Further evidence for betahistine's preventive effects in antipsychotic-induced weight gain Progressing intranasal...

Zug, Switzerland, November 08, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...

Bioavailability significantly higher than with oral administration Treatment safe and multiple dosing well tolerated Company to move forward with planned proof-of-concept studies in acute...

Zug, Switzerland, October 12, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...

Zug, Switzerland, August 30, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...

Dosing in second Phase 1 clinical trial with intranasal betahistine nearing completion Approaching important interactions with regulatory agencies Progressing with strategic repositioning of...

Zug, Switzerland, August 09, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...

Zug, Switzerland - July 12, 2018 - Auris Medical Holding AG (Nasdaq: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...